Cell surface binding and cellular internalization properties of suramin, a novel antineoplastic agent.
Although suramin has shown promise in preliminary clinical trials as an antineoplastic agent, it is unclear if its mode of action is predominately extracellular or intracellular. We have attempted to address this problem by studying the cellular pharmacology of tritiated suramin ([3H]suramin) in the DU145 and LNCaP prostate cancer cell lines, as well as in HL60 cells, an acute promyelocytic leukemia cell line. In the cell lines studied, significant, multisite, trypsin-insensitive, low-affinity cell surface binding by [3H]suramin was observed (Bmax > 10(6), Kd > 1 microM). The binding of [3H]suramin to the cell surface was competitive with respect to a phosphorothioate oligodeoxynucleotide homopolymer of cytidine, 28 bases in length, but was not affected by ATP. Use of this competitor allowed us to determine that [3H]suramin bound to the surface of HL60 cells was internalized via the process of adsorptive endocytosis and was maximal at approximately 6 h. In contrast, binding of suramin to the surface of the prostate cells, but not to that of HL60 cells, was completely abrogated by the presence of albumin (DU145 and LNCaP cells), or by warming to 37 degreesC (DU145 cells only). The dynamics of internalization and compartmentalization of suramin in DU145 revealed that within a narrow concentration range, internalization was dependent on time of exposure and drug concentration. Analysis of the exocytosis of suramin from DU145 cells revealed that approximately 64% of the drug was effluxed from a shallow compartment (t1/2 = 3.15 min) and 31% from a deep compartment (t1/2 = 433 min); both compartments probably represent endosomes. The results suggest that, because of the complexities of suramin's cellular pharmacology, its mechanism of action may vary signficantly according to cell type.
Stein
C A
CA
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.
Khan
T M
TM
Khaled
Z
Z
Tonkinson
J L
JL
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001667:Binding, Competitive; D002462:Cell Membrane / Q000378:metabolism*; D005089:Exocytosis; D018922:HL-60 Cells; D006801:Humans; D007700:Kinetics; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D011471:Prostatic Neoplasms; D013498:Suramin / Q000493:pharmacokinetics*; D013696:Temperature; D013873:Thionucleotides; D014316:Tritium
D000970:Antineoplastic Agents; D009838:Oligodeoxyribonucleotides; D013873:Thionucleotides; C033539:oligodeoxycytidylic acid; D014316:Tritium; D013498:Suramin